Added to YB: 2026-02-04
Pitch date: 2026-02-02
GOSS [neutral]
Gossamer Bio, Inc.
-14.92%
current return
Author Info
No bio for this author
Company Info
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
Market Cap
$523.1M
Pitch Price
$2.48
Price Target
8.67 (+311%)
Dividend
N/A
EV/EBITDA
-3.62
P/E
-3.29
EV/Sales
12.39
Sector
Biotechnology
Category
special_situation
Gossamer Bio, Inc. - $GOSS
GOSS: Biotech binary on seralutinib PAH inhaled therapy w/ PROSERA Phase 3 data Feb 2026. 390 patients, 6-min walk primary endpoint. CEO Hasnain sold Receptos for $7.2B. Chiesi partnership. Analysts: $8.67 avg PT vs $2.28 (280% upside). Risk: Phase 2 mixed efficacy. $180M cash runway.
Read full article (1 min)